Journal of International Psychiatry

Abstract: Objective: To observe the influence of fluoxetine combined risperdal in treatment of schizophrenia patients with anxiety and depression. Methods: 100 schizophrenia patients were retrospectively analyzed from May 2014 - April 2016 from in hospital, according to the dosing methods, all patients were divided into experimental group (n=50) and control group(n=50). The control group was given fluoxetine (20mg/times,1time/d) and placebo. Experimental group was given fluoxetine (20mg/time，1d/time)and risperdal (4mg/time, 1time/ d),two groups of treatment was 12 weeks. Used anxiety of hamilton depression rating scale HAMD and hamilton anxiety scale HAMA to evaluate patients with anxiety depression. Statistical analysis of all of the patients curative effect, HAMD and HAMA score, adverse reaction. Results: Total effective rate of of experimental group were higher than control group after treatment with statistical significance. The HAMD and HAMA score of experimental group were lower than control group after treatment of 4 and 12 weeks with statistical significance. Incidence of adverse reaction of experimental group patients there was no statistically significant difference with control group. Conclusion: Fluoxetine combined risperdal can effectively improve the curative effect of schizophrenia patients with anxiety, depression, promote recovery, safe and reliable, and it is worth further clinical application.

Keywords: fluoxetine; risperdal; schizophrenia; anxiety; depression